SPRING VALLEY, Calif., Nov. 6 /PRNewswire/ -- Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus.
Technology developed under this research project will enable an affordable FDA-approved method for diagnosing Dengue fever in blood/sera. This will enable medical personnel to adequately diagnose and react to Dengue fever outbreaks.
ABOUT CALBIOTECH: Calbiotech is a worldwide provider of Immunoassay products and services. The company offers ELISA, lumELISA(TM) (Ultra-Sensitive Chemiluminescent ELISA) and Radioimmunoassay (RIA) products, as well as preclinical testing services. Calbiotech’s product line includes: Endocrine, Steroid, Fertility, Cancer, Thyroid and Cardiac, Infectious Disease, Growth Hormone, Allergy and Drug of Abuse markers. The company also offers customized Immunoassay products for Mouse/Rat, Sheep, Canine, Porcine and other animal species that are used by major pharmaceutical companies, universities and research centers.
Additional information is available on the Internet at http://www.calbiotech.com.
This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.
Calbiotech, Inc.
